| | | | | | Note 15: | Earnings per Share |
Basic and diluted shares outstanding used in our earnings per share calculation are calculated as follows: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | For the Three Months Ended September 30, | | For the Nine Months Ended September 30, | | (In millions) | | 2026 | | 2025 | | 2026 | | 2025 | | Numerator: | | | | | | | | | | Net (loss) income attributable to Biogen Inc. | | $ | (20.6) | | | $ | 466.5 | | | $ | 396.4 | | | $ | 1,341.8 | | | Denominator: | | | | | | | | | | Weighted average number of common shares outstanding | | 147.8 | | | 146.6 | | | 147.5 | | | 146.4 | | | Effect of dilutive securities: | | | | | | | | | | | | | | | | | | | Time-vested restricted stock units | | — | | | 0.5 | | | 1.2 | | | 0.4 | | | | | | | | | | | | Performance stock units settled in stock | | — | | | — | | | 0.2 | | | — | | | Dilutive potential common shares | | — | | | 0.5 | | | 1.4 | | | 0.4 | | | Shares used in calculating diluted earnings per share | | 147.8 | | | 147.1 | | | 148.9 | | | 146.8 | |
Amounts excluded from the calculation of net income per diluted share because their effects were anti-dilutive were insignificant.
|